- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 528KB)
Sacituzumab govitecan – March 2022
Sacituzumab govitecan: Powder for injection 180 mg; Trodelvy®
Last updated
1 July 2022